Cargando…

High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo

INTRODUCTION: The Republic of the Congo detected its first case of coronavirus disease 2019 (COVID-19) on March 14, 2020, and within several weeks, the country had introduced protective measures that were still in force in July 2020. Over the course of time, the progression in the number of clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Batchi-Bouyou, Armel Landry, Lobaloba Ingoba, Line, Ndounga, Matthieu, Vouvoungui, Jeannhey Christevy, Mfoutou Mapanguy, Claujens Chastel, Boumpoutou, Kamal Rauchelvy, Ntoumi, Francine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833234/
https://www.ncbi.nlm.nih.gov/pubmed/33370565
http://dx.doi.org/10.1016/j.ijid.2020.12.065
_version_ 1783642019191586816
author Batchi-Bouyou, Armel Landry
Lobaloba Ingoba, Line
Ndounga, Matthieu
Vouvoungui, Jeannhey Christevy
Mfoutou Mapanguy, Claujens Chastel
Boumpoutou, Kamal Rauchelvy
Ntoumi, Francine
author_facet Batchi-Bouyou, Armel Landry
Lobaloba Ingoba, Line
Ndounga, Matthieu
Vouvoungui, Jeannhey Christevy
Mfoutou Mapanguy, Claujens Chastel
Boumpoutou, Kamal Rauchelvy
Ntoumi, Francine
author_sort Batchi-Bouyou, Armel Landry
collection PubMed
description INTRODUCTION: The Republic of the Congo detected its first case of coronavirus disease 2019 (COVID-19) on March 14, 2020, and within several weeks, the country had introduced protective measures that were still in force in July 2020. Over the course of time, the progression in the number of clinical cases has appeared to be lower than expected, although reverse transcription polymerase chain reaction (RT-PCR) testing has been somewhat limited. In order to evaluate the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the Congolese population, a seroprevalence study was conducted on healthy individuals from different districts of Brazzaville who were willing to know their COVID-19 infection status. METHODS: Oropharyngeal swab and blood samples were collected from 754 healthy volunteers between April 2020 and July 2020. The samples were analyzed for SARS-CoV-2 using a qualitative RT-PCR assay, and Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies were detected using two different rapid tests. RESULTS: A total of 56 participants (7.4%) tested positive for SARS-CoV-2. The remaining 698 participants (92.6%) had negative RT-PCR results; of these, 117 were found to have anti-SARS-CoV-2 antibodies using serological tests. For these RT-PCR-negative subjects, the seroprevalence of IgG and IgM was found to increase over time: from 1.7% and 2.5% in April, up to 14.2% and 17.6% in July, respectively. In April 2020, 5% of the women were found to have IgG or IgM antibodies, whereas the antibodies were not detected in any of the men. The seroprevalence in RT-PCR negative subjects was significantly higher in women within IgG (P = 0.012) and IgM (P = 0.045) over the first three months. CONCLUSION: The proportion of the population who seroconvert over the course of the first wave is an important data to predict the risk of future COVID-19 waves and this will facilitate the efficient use of limited resources in a low income country like the Republic of the Congo.
format Online
Article
Text
id pubmed-7833234
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-78332342021-01-26 High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo Batchi-Bouyou, Armel Landry Lobaloba Ingoba, Line Ndounga, Matthieu Vouvoungui, Jeannhey Christevy Mfoutou Mapanguy, Claujens Chastel Boumpoutou, Kamal Rauchelvy Ntoumi, Francine Int J Infect Dis Article INTRODUCTION: The Republic of the Congo detected its first case of coronavirus disease 2019 (COVID-19) on March 14, 2020, and within several weeks, the country had introduced protective measures that were still in force in July 2020. Over the course of time, the progression in the number of clinical cases has appeared to be lower than expected, although reverse transcription polymerase chain reaction (RT-PCR) testing has been somewhat limited. In order to evaluate the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the Congolese population, a seroprevalence study was conducted on healthy individuals from different districts of Brazzaville who were willing to know their COVID-19 infection status. METHODS: Oropharyngeal swab and blood samples were collected from 754 healthy volunteers between April 2020 and July 2020. The samples were analyzed for SARS-CoV-2 using a qualitative RT-PCR assay, and Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies were detected using two different rapid tests. RESULTS: A total of 56 participants (7.4%) tested positive for SARS-CoV-2. The remaining 698 participants (92.6%) had negative RT-PCR results; of these, 117 were found to have anti-SARS-CoV-2 antibodies using serological tests. For these RT-PCR-negative subjects, the seroprevalence of IgG and IgM was found to increase over time: from 1.7% and 2.5% in April, up to 14.2% and 17.6% in July, respectively. In April 2020, 5% of the women were found to have IgG or IgM antibodies, whereas the antibodies were not detected in any of the men. The seroprevalence in RT-PCR negative subjects was significantly higher in women within IgG (P = 0.012) and IgM (P = 0.045) over the first three months. CONCLUSION: The proportion of the population who seroconvert over the course of the first wave is an important data to predict the risk of future COVID-19 waves and this will facilitate the efficient use of limited resources in a low income country like the Republic of the Congo. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-05 2020-12-25 /pmc/articles/PMC7833234/ /pubmed/33370565 http://dx.doi.org/10.1016/j.ijid.2020.12.065 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Batchi-Bouyou, Armel Landry
Lobaloba Ingoba, Line
Ndounga, Matthieu
Vouvoungui, Jeannhey Christevy
Mfoutou Mapanguy, Claujens Chastel
Boumpoutou, Kamal Rauchelvy
Ntoumi, Francine
High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo
title High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo
title_full High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo
title_fullStr High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo
title_full_unstemmed High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo
title_short High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo
title_sort high sars-cov-2 igg/igm seroprevalence in asymptomatic congolese in brazzaville, the republic of congo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833234/
https://www.ncbi.nlm.nih.gov/pubmed/33370565
http://dx.doi.org/10.1016/j.ijid.2020.12.065
work_keys_str_mv AT batchibouyouarmellandry highsarscov2iggigmseroprevalenceinasymptomaticcongoleseinbrazzavilletherepublicofcongo
AT lobalobaingobaline highsarscov2iggigmseroprevalenceinasymptomaticcongoleseinbrazzavilletherepublicofcongo
AT ndoungamatthieu highsarscov2iggigmseroprevalenceinasymptomaticcongoleseinbrazzavilletherepublicofcongo
AT vouvounguijeannheychristevy highsarscov2iggigmseroprevalenceinasymptomaticcongoleseinbrazzavilletherepublicofcongo
AT mfoutoumapanguyclaujenschastel highsarscov2iggigmseroprevalenceinasymptomaticcongoleseinbrazzavilletherepublicofcongo
AT boumpoutoukamalrauchelvy highsarscov2iggigmseroprevalenceinasymptomaticcongoleseinbrazzavilletherepublicofcongo
AT ntoumifrancine highsarscov2iggigmseroprevalenceinasymptomaticcongoleseinbrazzavilletherepublicofcongo